FDA Grants Accelerated Approval for Combination Melanoma Therapy

The FDA has granted accelerated approval to Tudriqev, an oncolytic viral therapy, in combination with nivolumab. This new treatment is for adult patients with unresectable advanced cutaneous melanoma who have progressed on prior PD-1-blocking antibody regimens, offering an additional option for those with limited alternatives. Continued approval relies on confirmatory trials.